In September 2026, Ultragenyx Pharmaceutical received full U.S. FDA approval for FAYUVI (UX111), the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, along with a Priority Review Voucher. This approval not only addresses a previously untreated ultra-rare, fatal neurodegenerative disease but also expands Ultragenyx's commercial gene therapy portfolio and manufacturing footprint in the U.S. We'll now explore how FAYUVI's first-in-disease approval and the associated Priority Review Voucher affect Ultragenyx's existing investment narrative. The best AI stocks today may lie beyond giants like Nvidia and Microsoft.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。